Rationale and Design of the Türkiye Heart Failure (TURK‐HF) Registry

OpenAlex İngilizce

ABSTRACT Aims The Türkiye Heart Failure (TURK‐HF) registry aims to identify the sociodemographic and clinical characteristics, management strategies, and outcomes of patients with heart failure (HF) and to assess the implementation of evidence‐based HF therapies in Türkiye. Methods The TURK‐HF registry is a national, multicenter, prospective, observational study of unselected patients with HF regardless of ejection fraction. A total of 46 investigators from 38 centers in 22 cities across Türkiye participated in the registry. The study investigators will gain access to the electronic case report form via www.turkhf.com website using their usernames and passwords. The baseline assessment of the patients will include sociodemographic data, primary care access information, frailty assessment, health‐related quality of life questionnaire, HF‐related information, medical history and comorbidities, physical examination findings, electrocardiographic and echocardiographic data, H 2 FPEF score calculation, laboratory results, and medical and device‐based HF therapies. The management strategies and potential complications of patients hospitalized with acute HF will be systematically documented. Follow‐up data will be collected at regular outpatient visits every 6 months with a margin of error of 1 month. The clinical endpoints of the TURK‐HF registry were cardiovascular or all‐cause mortality, HF‐related hospitalizations, clinician‐interpreted outcomes, patient‐reported outcomes, and surrogate endpoints, either alone or in combination. The TURK‐HF registry was registered at ClinicalTrials.gov (ID: NCT06707220). Conclusion The TURK‐HF registry offers comprehensive and distinctive insights into contemporary HF clinical characteristics, diagnostic methods, treatments, and outcomes. This registry has the potential to influence implementation strategies, clinical research, and public policies across Türkiye.